Myeloproliferative neoplasm stem cells

Myeloproliferative neoplasm stem cells

Myeloproliferative neoplasms (MPNs) arise in the hematopoietic stem cell (HSC) compartment as a result of the acquisition of somatic mutations in a single HSC that provides a selective advantage to mutant HSC over normal HSC and promotes myeloid differentiation to engender a myeloproliferative pheno...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Mead, A, Mullally, A
Format:	Journal article
Wydane:	American Society of Hematology 2017

Podobne zapisy

Evolution of myeloproliferative neoplasms from normal blood stem cells
od: Sahand Hormoz, i wsp.
Wydane: (2024-12-01)

Loss of bone marrow mesenchymal stem cells in myeloproliferative neoplasms as an indicator of niche dysregulation
od: Bishop, E, i wsp.
Wydane: (2016)

Heterogeneity in myeloproliferative neoplasms: causes and consequences
od: O'Sullivan, J, i wsp.
Wydane: (2018)

Application of single-cell approaches to study myeloproliferative neoplasm biology
od: Royston, D, i wsp.
Wydane: (2021)

Myeloproliferative neoplasms
od: Nick Cross, (Coordinating Author)
Wydane: (2019-06-01)

Myeloproliferative neoplasms
od: Jean-Jacques Kiladjian
Wydane: (2018-06-01)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
od: Luca Malcovati, i wsp.
Wydane: (2014-11-01)

Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.
od: Richard K Lubberich, i wsp.
Wydane: (2018-01-01)

Single-cell methods in myeloproliferative neoplasms: old questions, new technologies
od: O'Sullivan, JM, i wsp.
Wydane: (2023)

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders
od: Cross, NCP, i wsp.
Wydane: (2021)

The microenvironment in myeloproliferative neoplasm
od: Simón Méndez-Ferrer, i wsp.
Wydane: (2018-06-01)

Spleen in myeloproliferative neoplasms
od: Giovanni Barosi
Wydane: (2018-06-01)

Epigenetics in myeloproliferative neoplasms
od: Graeme Greenfield, i wsp.
Wydane: (2023-07-01)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
od: Greenfield, G, i wsp.
Wydane: (2020)

Blood cell activation in myeloproliferative neoplasms
od: Francisco Cervantes, i wsp.
Wydane: (2009-11-01)

Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms
od: Naoimh Herlihy, i wsp.
Wydane: (2019-04-01)

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
od: Xiaoli Wang, i wsp.
Wydane: (2022-04-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
od: Butt, N, i wsp.
Wydane: (2019)

The Hematopoietic Niche in Myeloproliferative Neoplasms
od: Annette H. Schmitt-Graeff, i wsp.
Wydane: (2015-01-01)

Pathophysiology of thrombosis in myeloproliferative neoplasms
od: Raffaele Landolfi, i wsp.
Wydane: (2011-02-01)

Autoimmunity and the risk of myeloproliferative neoplasms
od: Sigurdur Y. Kristinsson, i wsp.
Wydane: (2010-07-01)

Interferons in the treatment of myeloproliferative neoplasms
od: Pankit Vachhani, i wsp.
Wydane: (2024-02-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
od: Daniel Prins, i wsp.
Wydane: (2020-02-01)

Neurological Findings in Myeloproliferative Neoplasms
od: Semra Paydas
Wydane: (2013-04-01)

Novel therapeutics in myeloproliferative neoplasms
od: Sangeetha Venugopal, i wsp.
Wydane: (2020-12-01)

Targeted therapies for myeloproliferative neoplasms
od: Bing Li, i wsp.
Wydane: (2019-07-01)

Molecular pathogenesis of the myeloproliferative neoplasms
od: Graeme Greenfield, i wsp.
Wydane: (2021-06-01)

CALR Mutations in Myeloproliferative Neoplasms
od: Ken-Hong Lim
Wydane: (2014-06-01)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
od: Gregor Hoermann, i wsp.
Wydane: (2015-01-01)

Classification and personalized prognosis in myeloproliferative neoplasms
od: Grinfeld, J, i wsp.
Wydane: (2018)

The Role of New Technologies in Myeloproliferative Neoplasms
od: Giuseppe A. Palumbo, i wsp.
Wydane: (2019-04-01)

The possible role of mutated endothelial cells in myeloproliferative neoplasms
od: Mirko Farina, i wsp.
Wydane: (2021-07-01)

Mechanisms of disease transformation in myeloproliferative neoplasms
od: O'Sullivan, J
Wydane: (2022)

Epigenetics and mutations in chronic myeloproliferative neoplasms
od: Alessandro M. Vannucchi, i wsp.
Wydane: (2011-10-01)

Omalizumab alleviates pruritus in myeloproliferative neoplasms
od: Anna Ravn Landtblom, i wsp.
Wydane: (2023-01-01)

Molecular basis of myelodysplastic/myeloproliferative neoplasms
od: Andreas Reiter, i wsp.
Wydane: (2009-12-01)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
od: Stefan N. Constantinescu, i wsp.
Wydane: (2021-06-01)

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
od: Stephen E. Langabeer PhD, FRCPath
Wydane: (2023-06-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
od: Sylvie Hermouet, i wsp.
Wydane: (2023-05-01)

Philadelphia-negative chronic myeloproliferative neoplasms
od: Rosane Isabel Bittencourt, i wsp.
Wydane: (2012-01-01)